143 related articles for article (PubMed ID: 16837557)
21. Nicotinic receptors as CNS targets for Parkinson's disease.
Quik M; Bordia T; O'Leary K
Biochem Pharmacol; 2007 Oct; 74(8):1224-34. PubMed ID: 17631864
[TBL] [Abstract][Full Text] [Related]
22. Selective down-regulation of [(125)I]Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine.
Mugnaini M; Garzotti M; Sartori I; Pilla M; Repeto P; Heidbreder CA; Tessari M
Neuroscience; 2006; 137(2):565-72. PubMed ID: 16289885
[TBL] [Abstract][Full Text] [Related]
23. Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.
Quik M; Bordia T; Forno L; McIntosh JM
J Neurochem; 2004 Feb; 88(3):668-79. PubMed ID: 14720216
[TBL] [Abstract][Full Text] [Related]
24. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
[TBL] [Abstract][Full Text] [Related]
25. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
[TBL] [Abstract][Full Text] [Related]
26. Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography.
Nguyen HN; Rasmussen BA; Perry DC
J Pharmacol Exp Ther; 2003 Dec; 307(3):1090-7. PubMed ID: 14560040
[TBL] [Abstract][Full Text] [Related]
27. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
28. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.
Grady SR; Salminen O; Laverty DC; Whiteaker P; McIntosh JM; Collins AC; Marks MJ
Biochem Pharmacol; 2007 Oct; 74(8):1235-46. PubMed ID: 17825262
[TBL] [Abstract][Full Text] [Related]
29. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.
Kulak JM; Sum J; Musachio JL; McIntosh JM; Quik M
J Neurochem; 2002 Apr; 81(2):403-6. PubMed ID: 12064487
[TBL] [Abstract][Full Text] [Related]
30. Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.
Vieira-Brock PL; McFadden LM; Nielsen SM; Ellis JD; Walters ET; Stout KA; McIntosh JM; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2015 Dec; 355(3):463-72. PubMed ID: 26391161
[TBL] [Abstract][Full Text] [Related]
31. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
32. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
33. r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.
Beckmann JS; Meyer AC; Pivavarchyk M; Horton DB; Zheng G; Smith AM; Wooters TE; McIntosh JM; Crooks PA; Bardo MT; Dwoskin LP
Neurochem Res; 2015 Oct; 40(10):2121-30. PubMed ID: 26227997
[TBL] [Abstract][Full Text] [Related]
34. Involvement of the alpha3 subunit in central nicotinic binding populations.
Whiteaker P; Peterson CG; Xu W; McIntosh JM; Paylor R; Beaudet AL; Collins AC; Marks MJ
J Neurosci; 2002 Apr; 22(7):2522-9. PubMed ID: 11923417
[TBL] [Abstract][Full Text] [Related]
35. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
36. Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.
McCallum SE; Parameswaran N; Bordia T; Fan H; Tyndale RF; Langston JW; McIntosh JM; Quik M
J Neurochem; 2006 Feb; 96(4):1028-41. PubMed ID: 16412091
[TBL] [Abstract][Full Text] [Related]
37. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration.
Quik M; Polonskaya Y; Gillespie A; K Lloyd G; Langston JW
Neuroscience; 2000; 100(1):63-72. PubMed ID: 10996459
[TBL] [Abstract][Full Text] [Related]
38. Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum.
O'Leary KT; Parameswaran N; Johnston LC; McIntosh JM; Di Monte DA; Quik M
J Pharmacol Exp Ther; 2008 Oct; 327(1):124-9. PubMed ID: 18606871
[TBL] [Abstract][Full Text] [Related]
39. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
Quik M; McIntosh JM
J Pharmacol Exp Ther; 2006 Feb; 316(2):481-9. PubMed ID: 16210393
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.
Whiteaker P; Jimenez M; McIntosh JM; Collins AC; Marks MJ
Br J Pharmacol; 2000 Oct; 131(4):729-39. PubMed ID: 11030722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
